N/A
Completed N=6
VircapSeq Virus Detection in Sézary Syndrome
Source: ClinicalTrials.gov NCT02836886 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants
Summary
This study will be using this technique, called "VirCapSeq-VERT" to analyze the white blood cells of patients with Sézary syndrome. This could provide the foundation for future studies looking to understand the role that viruses play in the origin of Sézary syndrome. This could have important implications for the future development of new and effective therapies for the disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome |
6 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with Sézary syndrome diagnosed according to the WHO-EORTC classification.
Exclusion Criteria
- Pregnant patients.
- Patients with known anemia with documented <7.5 mg/dL.
- Patients who are unable to give informed consent.
Data sourced from ClinicalTrials.gov (NCT02836886). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.